Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



These 5 Cancer Immunotherapy Companies All Have 1 Thing in Common

Change typically doesn't hit the health care industry all at once, but in practically a blink of an eye, cancer immunotherapies -- training the body's immune system to recognize and attack cancer -- are all the rage.

We can certainly point to the American Society of Clinical Oncology meeting in 2013 as the reason this treatment pathway took center stage, with Bristol-Myers Squibb's nivolumab and Merck's lambrolizumab, which both treat advanced types of melanoma, stealing the show. These two experimental therapies are part of an exciting class of PD-1 inhibitors which, in really early-stage studies, delivered stunning overall response rates (ORR). A phase 1 study that combined nivolumab with FDA-approved Yervoy delivered an ORR of 53%, while the optimal dosage of lambrolizumab produced an ORR of 52%.

Yet, the truth of the matter is that there are a number of advancing cancer immunotherapy studies currently under way from the likes of Dendreon (NASDAQOTH: DNDNQ  ) , Galena Biopharma (NASDAQ: GALE  ) , NewLink Genetics (NASDAQ: NLNK  ) , Peregrine Pharmaceuticals (NASDAQ: PPHM  ) , and Inovio Pharmaceuticals (NASDAQ: INO  ) as well. In other words, cancer immunotherapy studies aren't exclusive to Bristol and Merck.

Macrophages fusing with cancer cell. Source: Dr. Raowf Guirguis, Wikimedia Commons.

These companies share one common bond
However, these five immunotherapy-focused companies above do share a bond that extends beyond their research. This bond in question is that they're all relatively small ($1 billion in market value or less) all things considered, and that a majority of their valuation is based on the future success of one or two therapies within their respective pipelines.

Let's have a quick look at each pipeline so you can get a better idea of how much "hope" is really baked into each of their valuations. Keep in mind that my intent is not to pass judgment in a good or bad sense on any of these five immunotherapy-focused companies, but to instead highlight which one or two immunotherapy drug hopefuls could make or break these companies.

Dendreon is really the only established biopharma of the group, with its metastatic prostate cancer immunotherapy Provenge being approved by the FDA in April 2010. Dendreon's therapy works by collecting some of a patients' immune cells (a process known as leukapheresis), exposing those cells to a signature protein from the targeted cancer, and then reinjecting those immune cells so they can target prostate cancer cells. In trials, Provenge was shown to have improved median overall survival by a tad over four months.

Unfortunately for Dendreon, competition in treating metastatic prostate cancer has been increasing at a ferocious pace, and Dendreon didn't exactly handle its product launch very well. Peak sales expectations for its immunotherapy vaccine have fallen from $4.3 billion a few years ago to roughly 10% of that total today, even with its recent European approval. If Dendreon is unable to cut its costs with its second restructuring in as many years, the company's share price may have further downside.

Galena Biopharma
Galena might be the poster child for unbridled hopes and dreams in the biotech sector, with its share price both more than quadrupling and losing more than half of its value in just the past couple of months. There are a number of factors at work here for this volatility, but I'd surmise that the bulk of Galena's hope is built into the success or failure of its cancer immunotherapy NeuVax.

NeuVax is targeted at HER2-negative breast cancer patients (the predominant type of breast cancer) as an adjuvant therapy to help them maintain their disease-free status. Without getting too technical, NeuVax stimulates specific CD8+ cytotoxic T-lymphocytes causing them to recognize and destroy HER2-expressing cancer cells. In the final results from its phase 2 trial, Galena reports that at the 60-month mark, only 5.6% of NeuVax intent-to-treat subgroup of patients had a relapse, while 25.9% of patients in the control arm had a cancer reoccurrence. Overall, this represents a recurrence reduction of 78.4% in the target population and was more than enough to justify its ongoing phase 3 studies of the vaccine. It will still be a while before we have the results from Galena's phase 3 study, but NeuVax certainly has make-or-break potential for Galena.

NewLink Genetics
Unlike Dendreon and Galena, NewLink Genetics really has two products in its HyperAcute immunotherapy platform working side by side to give the company its current $1 billion valuation -- algenpantucel-L in two separate late-stage pancreatic cancer studies and tergenpumatucel-L in relapsed or refractory non-small cell lung cancer (NSCLC).

Source: Novartis.

NewLink's immunotherapy treatments work by modifying existing cancer cell lines to express alpha-gal, a carbohydrate that the human body has a natural immunity to. Once in the body, alpha-gals train the body to recognize these cancer cells and to seek out and destroy them. In early June, NewLink released phase 2 data on tergenpumatucel-L for NSCLC, noting that it delivered median overall survival of 11.3 months and long-term stable disease in eight of 28 evaluable patients.

Just days later, NewLink reported phase 2 data from a resected pancreatic cancer study involving algenpantucel-L, which demonstrated disease-free survival in 62% of patients after one year. The data also showed a median overall survival of 42 months in patients with elevated levels of anti-mesothelin antibodies, which was more than double the median overall survival of patients without elevated levels. NewLink's treatments are therefore very specialized, and based on its $1 billion valuation, hopes for its success run high.

Peregrine Pharmaceuticals
With the exception of Cotara and PGN650, an early-stage tumor imaging agent, Peregrine's entire valuation is based on immunotherapy agent bavituximab which is being tested in both first- and second-line non-small cell lung cancer, liver cancer, and HER2-negative breast cancer, to name a few studies.

Peregrine's bavituximab is unique in that it's a phosphatidylserine (PS)-targeting monoclonal antibody. In easier to understand terms, PS is an immunosuppressive molecule typically found inside healthy cells, but in tumor cells, it's located on the outside of the cell, providing immune response protection. Bavituximab aims to block this immunosuppressive response and allow the body's immune system to recognize and destroy these cancer cells.

No trial is currently more important to Peregrine than its second-line NSCLC study, which is currently in phase 3 trials. Although its phase 2 results were far more complicated than they should have been, the end result was a better-than-doubling in median overall survival to 12.1 months from 5.6 months in the control arm. Bavituximab also delivered a 40% increase in progression-free survival, to 4.2 months from 3.0 months. Without question, this phase 3 study will go a long way to proving or disproving the viability of Peregrine's immunotherapy.

Inovio Pharmaceuticals
Inovio Pharmaceuticals might be the one exception to the rule, here, since it has four cancer-focused immunotherapies in development in addition to a number of clinical and preclinical HIV and hepatitis-focused vaccines.

Inovio's claim to fame in this space is its SynCon vaccine platform, which utilizes synthetic DNA to target multiple disease antigens and break down whatever immune resistances may exist. The company's SynCon vaccines have thus far been developed to treat cervical dysplasia/cancer, as well as cancers that express hTERT such as breast, lung, and pancreatic cancer.

Despite having a number of existing trials, only one of Inovio's in-house studies has advanced beyond phase 1. However, this vaccine, VGX-3100, demonstrated incredibly promising early-stage immune responses to antigens from the human papillomavirus infection. Early data showed that VGX-3100 was effective at destroying precancerous cervical dysplasias that had been transformed by HPV, meaning it could have early- and later-stage success in treating cervical cancer.

Most cancer immunotherapy stocks have exploded higher recently, but even these aforementioned five companies may have trouble keeping up with this top stock
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Read/Post Comments (1) | Recommend This Article (6)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On February 19, 2014, at 3:37 AM, entheogenius wrote:

    Here's an excerpt from my journal and upcoming book "Psychopathis Psychotronics"

    7-13-07 cont'

    I just got sent to the group home and it's all male. Oh well, everyone seems nice enough.

    Here's another one of the ideas used against me. It was partly used as a basis for one of my psychiatric commitments and was made a part of my medical record.

    In 1987 at age 17 I read about Laetrile and Trophoblasts. Trophoblasts are supposedly a type of cell that play a crucial role in fetal development. Once that jobs done they just lay around in your body like a time bomb. If something comes along and wakes them up, they go into blastic replication and become cancer. Laetrile also known as Vitamin B-17 is a chemical sandwich with a cyanide molecule in the middle. To a non trophoblast cell laetrile is harmless, but to a trophoblast it's deadly because they produce the enzyme Beta-Glucoaronidase which is supposedly able to activate the cyanide in the laetrile delivering it right to the cancer cell or so that's the theory. It turned out to be b.s. or so they say. But it got me thinking about how some cancers are formed by viral activity. Cervical cancer from Human Papilloma Virus is a good example of this. It's my understanding that only a trophoblast can become cancerous.

    My idea was to make a virus that can only infect and replicate in a trophoblast by making them require the enzyme beta-glucoaronidase to initiate infection and replication. When a virus infects a cell it replaces its DNA with its RNA destroying the cell. Such a virus could theoretically cure cancer and vaccinate against it as well.

    I once told part of my theory to the resident psychiatrist at Hazelden rehab center in 1993. He wrote it down and bitched me out for keeping it a secret. About 18 months later in the news of the world of medicine section in the Readers Digest I read about a novel new cancer therapy involving injecting herpes viruses into brain tumors in rats and with promising results. By the way no one thought of me as having any mental illness at Hazelden.

    Cancer is expected to make around $160,000,000,000 per year by 2020 do you think anyone that's in on the profit wants to be replaced with an injection that may cost $20 to make per dose or less? How does that sound for being unable to differentiate between reality and fantasy?

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2842162, ~/Articles/ArticleHandler.aspx, 9/3/2015 7:42:38 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Sean Williams

A Fool since 2010, and a graduate from UC San Diego with a B.A. in Economics, Sean specializes in the healthcare sector and in investment planning topics. You'll usually find him writing about Obamacare, marijuana, developing drugs, diagnostics, and medical devices, Social Security, taxes, or any number of other macroeconomic issues.

Today's Market

updated Moments ago Sponsored by:
DOW 16,374.76 23.38 0.14%
S&P 500 1,951.13 2.27 0.12%
NASD 4,733.50 -16.48 -0.35%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/31/1969 7:00 PM
DNDNQ $0.03 Down +0.00 +0.00%
Dendreon Corp CAPS Rating: **
GALE $1.62 Down +0.00 +0.00%
Galena Biopharma,… CAPS Rating: *
INO $7.09 Down -0.14 -1.94%
Inovio Pharmaceuti… CAPS Rating: **
NLNK $44.47 Down -1.83 -3.95%
NewLink Genetics C… CAPS Rating: **
PPHM $1.17 Down -0.04 -3.31%
Peregrine Pharmace… CAPS Rating: **